Dual A2A/H3 Antagonist
Parkinson’s Disease
PreclinicalActive
Key Facts
About Palo BioFarma
Palobiofarma is a private, clinical-stage biotech company targeting rare diseases through selective adenosine receptor modulation. Its lead candidate, PBF-999, is in clinical development for Prader-Willi Syndrome, and the company has recently completed a research project on a dual A2A/H3 antagonist for Parkinson's disease. The company employs a lean, virtual R&D model, focusing internal expertise on drug design and chemistry while outsourcing later-stage preclinical work to CROs and academic partners. Its vision is to bring the first marketed selective adenosine receptor modulator to patients.
View full company profileTherapeutic Areas
Other Parkinson’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| hEN1 | BrainEver | Discovery |
| FGF-based Therapeutic | Venturis Therapeutics | Pre-clinical |
| Blarcamesine (ANAVEX®2-73) | Anavex Life Sciences | Phase 2 |